10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations [Yahoo! Finance]
10x Genomics, Inc. (TXG)
Last 10x genomics, inc. earnings: 2/18 04:01 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
6 min read In This Article TXG 10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses Expectations Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results beating Wall Street's revenue expectations , but sales fell by 10.3% year on year to $165 million. On the other hand, the company's full-year revenue guidance of $620 million at the midpoint came in 1.6% below analysts' estimates. Its GAAP loss of $0.40 per share was 34.4% below analysts' consensus estimates. Is now the time to buy 10x Genomics? Find out in our full research report 10x Genomics (TXG) Q4 CY2024 Highlights: Revenue: $165 million vs analyst estimates of $159.5 million (10.3% year-on-year decline, 3.5% beat) EPS (GAAP): -$0.40 vs analyst expectations of -$0.30 (34.4% miss) Management's revenue guidance for the upcoming financial year 2025 is $620 million at the midpoint, missing analyst estimates by 1.6% and implying 1.5% growth (vs -0.6% in FY2024) Operat
Show less
Read more
Impact Snapshot
Event Time:
TXG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TXG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TXG alerts
High impacting 10x Genomics, Inc. news events
Weekly update
A roundup of the hottest topics
TXG
News
- 10x Genomics (NASDAQ:TXG) had its "overweight" rating reaffirmed by analysts at Barclays PLC.MarketBeat
- 10x Genomics (NASDAQ:TXG) was downgraded by analysts at Citigroup Inc. from a "buy" rating to a "cautious" rating.MarketBeat
- 10x Genomics (NASDAQ:TXG) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..MarketBeat
- 10x Genomics (NASDAQ:TXG) was given a new $20.00 price target on by analysts at Morgan Stanley.MarketBeat
- 10x Genomics (NASDAQ:TXG) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
TXG
Earnings
- 11/6/25 - Beat
TXG
Sec Filings
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- 11/25/25 - Form 4
- TXG's page on the SEC website